Skip to Main Content
Contribute Try STAT+ Today

For the second time in two weeks, patient groups in India are raising concerns about a domestic vaccine manufacturer and its Covid-19 shot, which is one of two vaccines that were recently granted emergency use by the Indian government for combating the pandemic.

The latest flap involves allegations that Bharat Biotech failed to follow proper procedures for providing informed consent to clinical trial participants and, consequently, that the company is violating national guidelines. Advocates, who note many participants lacked the education to understand consent forms, say they are concerned about the ethics of offering low-income individuals a “substantial” sum of money to be vaccinated as part of the study.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.